Current chemotherapeutic strategies against various intractable
cancers are futile due to inefficient delivery, poor bioavailability,
and inadequate accumulation of anticancer drugs in the diseased site
with toxicity caused to the healthy neighboring cells. Drug delivery
systems aiming to deliver effective therapeutic concentrations to
the site of action have emerged as a promising approach to address
the above-mentioned issues. Thus, as several receptors have been identified
as being overexpressed on cancer cells including folate receptor (FR),
where up to 100–300 times higher overexpression is shown in
cancer cells compared to healthy cells, approximately 1–10
million receptor copies per cancer cell can be targeted by a folic
acid (FA) ligand. Herein, we developed FA-decorated and doxorubicin-conjugated
polymeric micelles of 30 nm size. The hydrophilic block comprises
poly(ethylene glycol) units, and the hydrophobic block contains doxorubicin
conjugated aspartic acid units. Decoration of FA
on the micelle surface induces ligand–receptor interaction,
resulting in enhanced internalization into the cancer cell and inside
the endolysosomal compartment. Under acidic pH, the micelle structure
is disrupted and the hydrazone bond is cleaved, which covalently binds
the doxorubicin with the hydrophobic backbone of the polymer and release
the drug. We observed that the cellular uptake and nuclear colocalization
of the targeted micelle are 2–4 fold higher than the control
micelle at various incubation times in FR-overexpressed various cancer
cell lines (KB, HeLa, and C6). These results indicate significant
prospects for anticancer therapy as an effective and translational
treatment strategy.